BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35976464)

  • 1. Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.
    Borella F; Cosma S; Ferraioli D; Ray-Coquard I; Chopin N; Meeus P; Cockenpot V; Valabrega G; Scotto G; Turinetto M; Biglia N; Fuso L; Mariani L; Franchi D; Vidal Urbinati AM; Pino I; Bertschy G; Preti M; Benedetto C; Castellano I; Cassoni P; Bertero L
    Ann Surg Oncol; 2022 Dec; 29(13):8302-8314. PubMed ID: 35976464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.
    Raspagliesi F; Maltese G; Bogani G; Fucà G; Lepori S; De Iaco P; Perrone M; Scambia G; Cormio G; Bogliolo S; Bergamini A; Bifulco G; Casali PG; Lorusso D
    Gynecol Oncol; 2017 Jan; 144(1):90-95. PubMed ID: 27817933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
    Ip PP; Cheung AN; Clement PB
    Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
    Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis.
    Basaran D; Usubutun A; Salman MC; Narin MA; Boyraz G; Turkmen O; Comert Kimyon G; Karalok A; Bulbul D; Turan T; Ozgul N; Yuce K
    Int J Gynecol Cancer; 2018 Feb; 28(2):233-240. PubMed ID: 29303932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
    Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
    Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
    Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
    Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine smooth muscle tumor of uncertain malignant potential: A review of current knowledge.
    Liu HT; Wong CN; Wong CN; Liu FS
    Taiwan J Obstet Gynecol; 2022 Nov; 61(6):935-940. PubMed ID: 36427995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
    Petrović D; Babić D; Forko JI; Martinac I
    Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience of uterine smooth muscle tumor of uncertain malignant potential in two gynecological centers: Oncological and obstetrical aspects.
    Shim JI; Han AKW; Jeon HJ; Kim ML; Jung YW; Yun BS; Seong SJ; Shin E; Cho YJ; Rha SH
    Eur J Obstet Gynecol Reprod Biol; 2020 Mar; 246():7-13. PubMed ID: 31927240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
    Mittal K; Demopoulos RI
    Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
    Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
    J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine smooth muscle tumor of uncertain malignant potential: fertility and clinical outcomes.
    Şahin H; Karatas F; Coban G; Özen Ö; Erdem Ö; Onan MA; Ayhan A
    J Gynecol Oncol; 2019 Jul; 30(4):e54. PubMed ID: 31074239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis.
    Guntupalli SR; Ramirez PT; Anderson ML; Milam MR; Bodurka DC; Malpica A
    Gynecol Oncol; 2009 Jun; 113(3):324-6. PubMed ID: 19342083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors.
    Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of morcellation of uterine smooth muscle tumor of uncertain malignant potential and endometrial stromal sarcoma: case series and recommendations for clinical practice.
    Mowers EL; Skinner B; McLean K; Reynolds RK
    J Minim Invasive Gynecol; 2015; 22(4):601-6. PubMed ID: 25596464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.